1. Updates on the Use of Adjuvant Therapy in HER2-Positive Breast Cancer

3. ASCO-CAP Recommendations For HER2 Testing in Breast Cancer

4. Criteria For Reporting HER2 Test Results as Positive

5. Criteria for Reporting HER2 Test Results as Negative

6. Criteria for Reporting Equivocal Results

7. Criteria for Reporting Indeterminate Results

8. NSABP B-47 Findings

9. ASCO Recommendations for Adjuvant Therapy for HER2-Positive Breast Cancer

10. ASCO Recommendations for Adjuvant Therapy for HER2-Positive Breast Cancer (cont)

11. APT Trial

12. Updated Analysis of APT Trial

13. APHINITY Trial

14. APHINITY Results

15. Invasive DFS at 3 Years

16. APHINITY Safety Data

17. Most Common Grade ≥ 3 AEs

18. NeoSphere Trial

19. NeoSphere Results

20. ExteNET Trial

21. ExteNET Trial Amendments

22. Baseline Characteristics

23. ExteNET Results

24. ExteNET: AEs

25. Preventing Neratinib-Associated Diarrhea: The CONTROL Trial

26. CONTROL: Results of Interim Analysis Reported at 2017 AACR

27. CONTROL: Results of Interim Analysis Reported at 2017 AACR (cont)

28. Take-Home Messages

29. Take-Home Messages (cont)

30. Abbreviations

31. Abbreviations (cont)